Li Z, Wang Y, Sun Y, Wang L, et al. Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study. Lancet Oncol 2025 Feb 25:S1470-2045(25)00012.
PMID: 40020696